Is there a need for an alternative in the era of novel anticoagulants?

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 9, 2015, Pages 967-970

  Ansell, Jack ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

anticoagulants; direct oral anticoagulants; DOACs; NOACs; novel oral anticoagulants

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; COAGULATION IMPAIRMENT; HUMAN; REVIEW; RISK FACTOR; DRUG DEVELOPMENT; DRUG INTERACTION; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTITHROMBINS; DRUG DISCOVERY; DRUG INTERACTIONS; HEMORRHAGE; HUMANS;

EID: 84940509385     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1069707     Document Type: Review

References (30)

1. Weitz JI. New anticoagulants for treatment of venous thromboembolism. Circulation 2004;110(Suppl 1):I-19-26
2. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: Opportunities and challenges. Arterioscler Thromb Vasc Biol 2015;35:1056-65
3. Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against J Thromb Haemost 2010;8:627-30
4. Hawes EM, Deal AM, Funk-Adcock D, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost 2013;11:1493-502
5. Douxfils J, Mullier F, Robert S, et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012;107:985-97
6. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128-39
7. Costin J, Ansell J, Laulicht B, et al. Reversal agents in development for the new oral anticoagulants. Postgrad Med 2014;126(7): 19-24
8. Diamandis EP, Christopoulos TK. The biotin-(strept)avidin system: Principles and applications in biotechnology. Clin Chem 1991;37:625-36
9. Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb Haemost 2009;102: 811-15
10. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8:722-9
11. Buller HR, Gallus AS, Pillion G, et al. Enoxaparin followed by once weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomized, double-blind, double-dummy, non-inferiority trial. Lancet 2012;379:123-9
12. Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Thromb Haemost 2005;93: 1014-20
13. Povsic TJ, Vavalle JP, Aberle LH, et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Euro Heart J 2013;34: 2481-9
14. Vavalle JP, Rusconi CP, Zelenkofske S, et al. The effect of the REG2 anticoagulation system on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study. J Thromb Thrombolysis 2014;38:275-84
15. Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol 2010;30:382-7
16. Sise HS, Lavelle SM, Adamis D, Becker R. Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. N Engl J Med 1958;259:266-71
17. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3-suppl):204S-33S
18. Lowenberg EC, Meijers JCM, Monia BP, Levi M. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 2010;8:2349-57
19. Schumacher WA, Luettgen JM, Quan ML, Seiffert DA. Inhibition of factor XIa as a new approach to anticoagulation. Arterioscler Thromb Vasc Biol 2010;30: 388-92
20. van Montfoort ML, Meijers JCM. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? Thromb Haemost 2013;110:223-323
21. Wong PC, Crain EJ, Watson CA, Schumacher WA. A small molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis 2011;32:129-37
22. Zhang H, Lowenberg EC, Crosby JR, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010;116:4684-92
23. Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thrombo Vasc Biol 2013;33: 1670-8
24. Buller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015;372:232-40
25. Cho J. Protein disulfide isomerase in thrombosis and vascular inflammation. J Thromb Haemost 2013;11:2084-91
26. Flaumenhaft R, Furie B, Zwicker JI. Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease. Arterioscler Thromb Vasc Biol 2015;35: 16-23
27. Smith SA, Morrissey JH. Polyphosphate: A novel modulator of hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2015;35:1298-305
28. Tavers RJ, Shenoi RA, Kalathottukaren MT, et al. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014;124:3183-90
29. Available from: www.anticoagulationhub. com/index.php? id=20043&type=98&tx-ttnews[tt-news]= 213626&cHash=da03e20e36 [Last accessed 10 June 2015]
30. Porter ME. What is value in health care? N Engl J Med 2010; 363: 2477-81